• 1
    Auvinen E, Niemi M, Malm C, et al. High prevalence of HPV among female students in Finland. Scand J Infect Dis 2005;37:8736.
  • 2
    Kjaer SK, Munk C, Winther JF, et al. Acquisition and persistence of human papillomavirus infection in younger men: A prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005;14:152833.
  • 3
    Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003;88:6373.
  • 4
    Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:92735.
  • 5
    Arbyn M, Sanjose SD, Saraiya M, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 2012;131:196982.
  • 6
    Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32 Suppl 1:S16S24.
  • 7
    Smith JS, Backes DM, Hoots BE, et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009;113:91724.
  • 8
    Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:267586.
  • 9
    Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002;29:72535.
  • 10
    Weaver BA, Feng Q, Holmes KK, et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis 2004;189:67785.
  • 11
    Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:191527.
  • 12
    Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009;374:30114.
  • 13
    Hakama M, Rasanen-Virtanen U. Effect of a mass screening program on the risk of cervical cancer. Am J Epidemiol 1976;103:5127.
  • 14
    Anttila A, Pukkala E, Soderman B, et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: Recent increase in cervical cancer incidence. Int J Cancer 1999;83:5965.
  • 15
    Cervical cancer incidence in Finland. NORDCAN: Cancer incidence, mortality, prevalence and survival in the Nordic countries Association of the Nordic Cancer Registries. 2012. Available from:
  • 16
    Hujanen T, Kapiainen S, Tuominen U, et al, eds. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006, Helsinki: National Research and Development Centre for Welfare and Health (STAKES), 2008.
  • 17
    Lonnberg S, Leinonen M, Malila N, et al. Validation of histological diagnoses in a national cervical screening register. Acta Oncol 2012;51:3744.
  • 18
    Desai S, Wetten S, Woodhall SC, et al. Genital warts and cost of care in England. Sex Transm Infect 2011;87:4648.
  • 19
    Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102:32539.
  • 20
    Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:157685.
  • 21
    Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: A nested analysis within the Costa Rica vaccine trial. Lancet Oncol 2011;12:86270.
  • 22
    Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-advisory committee on immunization practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:17058.
  • 23
    Lonnberg SV, Anttila A, Luostarinen T, et al. Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev 2012 Jun 4.
  • 24
    Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:4238.
  • 25
    Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:48590.
  • 26
    Winer RL, Hughes JP, Feng Q, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011;20:699707.
  • 27
    Albrechtsen S, Rasmussen S, Thoresen S, et al. Pregnancy outcome in women before and after cervical conisation: Population based cohort study. BMJ 2008;337:a1343.
  • 28
    Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomized, double-blind PATRICIA trial. Lancet Oncol 2012;13:8999.